

Hok Pan Yuen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2987415/publications.pdf>

Version: 2024-02-01

25
papers

4,834
citations

471061

17
h-index

580395

25
g-index

27
all docs

27
docs citations

27
times ranked

3291
citing authors

#	ARTICLE	IF	CITATIONS
1	Twelve-Month Cognitive Trajectories in Individuals at Ultra-High Risk for Psychosis: A Latent Class Analysis. <i>Schizophrenia Bulletin Open</i> , 2022, 3, .	0.9	2
2	Omega-3 fatty acids and neurocognitive ability in young people at ultra-high risk for psychosis. <i>Microbial Biotechnology</i> , 2021, 15, 874-881.	0.9	10
3	Prediction of clinical outcomes beyond psychosis in the ultra-high risk for psychosis population. <i>Microbial Biotechnology</i> , 2021, 15, 642-651.	0.9	11
4	Differentiating the effect of antipsychotic medication and illness on brain volume reductions in first-episode psychosis: A Longitudinal, Randomised, Triple-blind, Placebo-controlled MRI Study. <i>Neuropsychopharmacology</i> , 2021, 46, 1494-1501.	2.8	44
5	Cognitive ability and metabolic physical health in first-episode psychosis. <i>Schizophrenia Research: Cognition</i> , 2021, 24, 100194.	0.7	5
6	Comparison of erythrocyte omega-3 index, fatty acids and molecular phospholipid species in people at ultra-high risk of developing psychosis and healthy people. <i>Schizophrenia Research</i> , 2020, 226, 44-51.	1.1	27
7	Dynamic prediction systems of transition to psychosis using joint modelling: extensions to the base system. <i>Schizophrenia Research</i> , 2020, 216, 207-212.	1.1	3
8	Psychosocial Intervention With or Without Antipsychotic Medication for First-Episode Psychosis: A Randomized Noninferiority Clinical Trial. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	0.9	45
9	Cognitive functioning in ultra-high risk for psychosis individuals with and without depression: Secondary analysis of findings from the NEURAPRO randomized clinical trial. <i>Schizophrenia Research</i> , 2020, 218, 48-54.	1.1	8
10	Pluripotential Risk and Clinical Staging: Theoretical Considerations and Preliminary Data From a Transdiagnostic Risk Identification Approach. <i>Frontiers in Psychiatry</i> , 2020, 11, 553578.	1.3	30
11	Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial. <i>Schizophrenia Research</i> , 2019, 206, 67-74.	1.1	46
12	Longitudinal Cognitive Performance in Individuals at Ultrahigh Risk for Psychosis: A 10-year Follow-up. <i>Schizophrenia Bulletin</i> , 2019, 45, 1101-1111.	2.3	27
13	Staged treatment and acceptability guidelines in early psychosis study (STAGES): A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first-episode psychosis with low risk of self-harm or aggression. Study protocol and baseline characteristics of participants. <i>Microbial Biotechnology</i> , 2019, 13, 953-960.	0.9	19
14	Staged Treatment in Early Psychosis: A sequential multiple assignment randomised trial of interventions for ultra high risk of psychosis patients. <i>Microbial Biotechnology</i> , 2018, 12, 292-306.	0.9	52
15	A new method for analysing transition to psychosis: Joint modelling of time-to-event outcome with time-dependent predictors. <i>International Journal of Methods in Psychiatric Research</i> , 2018, 27, .	1.1	19
16	Dynamic prediction of transition to psychosis using joint modelling. <i>Schizophrenia Research</i> , 2018, 202, 333-340.	1.1	18
17	NEURAPRO study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. <i>Microbial Biotechnology</i> , 2017, 11, 418-428.	0.9	55
18	Effect of ω -3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders. <i>JAMA Psychiatry</i> , 2017, 74, 19.	6.0	216

#	ARTICLE	IF	CITATIONS
19	Declining transition rates to psychotic disorder in "ultra-high risk" clients: Investigation of a dilution effect. <i>Schizophrenia Research</i> , 2016, 170, 130-136.	1.1	87
20	Performance of joint modelling of time-to-event data with time-dependent predictors: an assessment based on transition to psychosis data. <i>PeerJ</i> , 2016, 4, e2582.	0.9	25
21	Long-term Follow-up of a Group at Ultra High Risk ("Prodromal") for Psychosis. <i>JAMA Psychiatry</i> , 2013, 70, 793.	6.0	373
22	Declining Transition Rate in Ultra High Risk (Prodromal) Services: Dilution or Reduction of Risk?. <i>Schizophrenia Bulletin</i> , 2007, 33, 673-681.	2.3	376
23	Mapping the Onset of Psychosis: The Comprehensive Assessment of At-Risk Mental States. <i>Australian and New Zealand Journal of Psychiatry</i> , 2005, 39, 964-971.	1.3	1,677
24	Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. <i>Schizophrenia Research</i> , 2004, 67, 131-142.	1.1	673
25	Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. <i>Schizophrenia Research</i> , 2003, 60, 21-32.	1.1	981